Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599138 | 0.85 | HCAR3 (1.00) | HCAR3HPGDMAPTPOLBSMN1; SMN2 | |
| SCHEMBL12369468 | 0.85 | HCAR3 (0.76) | HCAR3HPGDMAPTPOLBSMN1; SMN2 | |
| SCHEMBL29751005 | 0.83 | HCAR3 (0.73) | HCAR3HPGDMAPTPOLBSMN1; SMN2 | |
| SCHEMBL21409085 | 0.83 | HCAR3 (0.73) | HCAR3HPGDMAPTPOLBSMN1; SMN2 | |
| SCHEMBL2876917 | 0.81 | HCAR3 (0.69) | HCAR3HPGDMAPTPOLBSMN1; SMN2 | |
| SCHEMBL1020492 | 0.80 | HCAR3 (0.76) | HCAR3HPGDMAPTPOLBSMN1; SMN2 | |
| SCHEMBL30767829 | 0.80 | MAPT (0.70) | HCAR3HPGDMAPTPOLBSMN1; SMN2 | |
| SCHEMBL29069383 | 0.80 | MAPT (0.70) | HCAR3HPGDMAPTPOLBSMN1; SMN2 | |
| SCHEMBL27688175 | 0.77 | HCAR3 (0.49) | HCAR3HPGDMAPTPOLBSMN1; SMN2 | |
| SCHEMBL28782983 | 0.77 | HCAR3 (0.64) | HCAR3HPGDMAPTPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118879386-B | Emulsified oil for hydraulic support and preparation method thereof | 圣保路石油化工（天津）股份有限公司 | 2024-12-24 | — | — | CN | claimed |
| CN-118879386-A | Emulsified oil for hydraulic support and preparation method thereof | 圣保路石油化工（天津）股份有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-118879386-B | Emulsified oil for hydraulic support and preparation method thereof | 圣保路石油化工（天津）股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| CN-118879386-A | Emulsified oil for hydraulic support and preparation method thereof | 圣保路石油化工（天津）股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8198287-B2 | Substituted heteroaryl pyridopyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-1567496-B1 | PHENYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2007-04-11 | — | — | EP | disclosed |
| US-7176316-B2 | Amino-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1594840-B1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | disclosed |
| US-20060014789-A1 | Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | US | disclosed |
| EP-1594840-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| EP-1567496-A1 | PHENYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS | AstraZeneca AB (SE) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004072034-A1 | PIPERIDINE-BENZENESULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-26 | — | — | WO | disclosed |
| US-20040167166-A1 | Amino-piperidine derivatives | HOFFMANN-LA ROCHE INC. | 2004-08-26 | — | — | US | disclosed |
| WO-2004041784-A1 | PHENYL-PIPERIDIN-4-YLIDENE-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167166-A1 | Amino-piperidine derivatives | OPRL1, GRIA1, GRIN1 | HCAR3 1938/4885HPGD 2870/4885MAPT 64/4885 |
| US-20060014789-A1 | Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders | TRPV1, TRPA1, OPRM1 | HCAR3 1042/4885HPGD 1452/4885MAPT 3436/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | HCAR3 1231/4885HPGD 2604/4885MAPT 1870/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | HCAR3 1231/4885HPGD 2604/4885MAPT 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.